Clinical Research Directory

Inclusion Criteria: 1. Voluntarily participate in this study and sign the informed consent form. 2. Age ≥ 18 years at the time of screening, male or female. 3. Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and \<180 mmHg. 4. During the run-in period, adherence to baseline antihypertensive medications and study medications ranged from 80% to 120% (including the boundary values); 5. There were no changes in the types or doses of baseline antihypertensive medications prior to randomization, and no rescue therapy was administered. Exclusion Criteria: 1. Known causes of secondary hypertension: renal artery stenosis, primary aldosteronism, Cushing's syndrome, pheochromocytoma, aortic coarctation, etc.; 2. Allergic constitution (allergies to ≥3 types/classes of drugs or foods); or known allergy to aldosterone synthase inhibitors or background antihypertensive medications; 3. History of malignancy within the past 5 years, or a potential malignancy currently under evaluation; 4. Type 2 diabetes with poor glycemic control, unstable antidiabetic treatment regimens within 4 weeks prior to screening, or type 1 diabetes; 5. Hyperthyroidism or hypothyroidism requiring immediate treatment or medication adjustment; or subclinical hypothyroidism with a TSH level \>10.0 mIU at screening or requiring medication as assessed by the investigator; 6. Severe cardiovascular or cerebrovascular disease within 6 months prior to screening; 7. Individuals who plan to conceive (including through sperm or egg donation) from the signing of the ICF until 3 months after the last dose of the investigational drug, and/or who do not agree to use effective non-pharmacological contraception; 8. Pregnant or breastfeeding women.